3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
7
Pancreatic Neoplasms
4
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Trastuzumab
3
pembrolizumab
2
Paclitaxel
2
Nivolumab
2
Interleukin-12 Subunit p35
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
trastuzumab deruxtecan
1
tivozanib
1
tipifarnib
1
seribantumab
1
sargramostim
1
pertuzumab
1
lenvatinib
1
entinostat
1
atezolizumab
1
Thalidomide
1
Specimen Handling
1
Psychiatric Rehabilitation
1
Peripheral Blood Stem Cell Transplantation
1
Oxaliplatin
1
Mesna
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Interleukin-12
1
Immunohistochemistry
1
Ifosfamide
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
pertuzumab
×
Genitourinary
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled